Spots Global Cancer Trial Database for 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)
Official Title: Phase II-Study With Nelarabine in Patients With Refractory Oder Relapsed T- ALL or T-lymphoblastic Lymphoma (Amend.7)
Study ID: NCT00684619
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether Nelarabine is effective in the treatment of patients with T-ALL/NHL in order to achieve a complete remission followed by an early stem cell transplantation.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Robert Bosch Krankenhaus, Stuttgart, Baden-Württemberg, Germany
Klinikum der Universität Regensburg, Regensburg, Bayern, Germany
University Hospital of Frankfurt, Medical Dept. II, Frankfurt, Hessen, Germany
Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
Universitätsklinikum Essen, Essen, NRW, Germany
Universitätsklinik Münster, Münster, NRW, Germany
Universitätsklinik Dresden, Dresden, Sachsen, Germany
Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany
Universitätsklinikum Kiel, Kiel, Schleswig-Holstein, Germany
Klinikum der FSU Jena, Jena, Thüringen, Germany
HELIOS Klinikum Berlin-Buch, Berlin, , Germany
Contact Details
Name: Dieter Hoelzer, MD, PhD
Affiliation: University Hospital of Frankfurt, Medical Dept. II
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
